Sells it, part of MedTech“This portfolio includes instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies designed to support procedural consistency and efficiency across multiple surgical specialties.”
Latest 10-KFY2025 ·
DARZALEX and CARVYKTI growth offset STELARA’s biosimilar-driven decline; a talc reserve reversal boosted earnings without lifting operating cash flow.
Sells it“Novanta acquired Riverpoint Medical, a supplier of minimally invasive surgical consumables, on July 23, 2026, for $1,200.6M of upfront cash consideration, net of cash acquired.”
Latest 10-QQ3 FY2026Restructuring ·
Riverpoint expands surgical consumables, but acquisition charges, amortization and financing costs overwhelm gains from stronger automation.
Sells it 18%, $1.2B a quarter“Instruments included Q3 Neuro Cranial revenue of $670 versus $637 and Enabling Technologies revenue of $28 versus $45; 9M amounts were $1,957 versus $1,816 and $82 versus $108.”